Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
Aaron P MitchellSonia PersaudPaul PalycaAndrew SalnerAzeez FarookiJamie S OstroffMichael J MorrisSusan ChimonasPublished in: The Prostate (2023)
Awareness of guideline recommendations for screening and treatment of low bone mineral density and against BMA use for CSPC was good, but not complete. Dental navigation, peer-to-peer education, and EMR-based guidance were preferred intervention strategies to improve guideline-concordant use.